Table 2. Univariate and multivariate analyses of baseline and GPX2 expression parameters, and progression free survival in 169 TUR patients.
| Parameters | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age, 72 ≤ vs. < 71 | 1.04 | 0.57-1.90 | 0.89 | 0.92 | 0.51-1.72 | 0.83 |
| Gender, male vs. female |
0.50 | 0.27-0.93 | 0.03* | 0.53 | 0.28-1.02 | 0.06 |
| Urine cytology, positive and suspicious positive vs. negative | 4.90 | 1.52-15.9 | 0.0079** | 3.43 | 0.99-11.9 | 0.051 |
| Tumor multiplicity, multiple vs. solitary | 1.86 | 0.92-3.78 | 0.09 | 1.58 | 0.76-3.27 | 0.22 |
| Tumor grade, high vs. low | 4.0 | 0.97-16.5 | 0.06 | 1.32 | 0.28-6.22 | 0.72 |
| Concomitant of CIS, yes vs. no | 0.90 | 0.12-6.53 | 0.92 | 0.66 | 0.09-4.92 | 0.69 |
| Expression of GPX2, higher vs. lower | 0.41 | 0.22-0.78 | 0.0061** | 0.49 | 0.25-0.97 | 0.039* |
CIS: Carcinoma in situ, GPX2: Glutathione peroxidase 2, TUR: Transurethral resection of bladder cancer, HR: Hazards ratio, CI: Confidence interval. *p<0.05, **p<0.01 indicates a significant difference.